Journal
SCIENCE
Volume 321, Issue 5891, Pages 974-977Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1158545
Keywords
-
Categories
Ask authors/readers for more resources
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non- Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell- engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available